The PREDICT Registry:

This study is looking at how a specific genetic test, called DCISionRT, helps doctors and patients make decisions about treating ductal carcinoma in situ, often referred to as DCIS or Stage 0 breast cancer. DCISionRT looks at seven different genes in your tumor tissue to predict the risk of the cancer returning and whether radiation therapy is likely to be beneficial for you. Because this is an observational study, it does not change the medical care you receive. Instead, researchers will ask your doctor to complete surveys before and after they see your test results to see if the information changed your recommended treatment plan.

To be eligible, you must be between 30 and 85 years old and have a recent diagnosis of DCIS in one breast that is smaller than six centimeters. You must be a candidate for breast-conserving surgery, such as a lumpectomy, and be eligible for radiation or hormone therapy. Patients who have already had a mastectomy, those with invasive breast cancer, or those who have had breast cancer in the past are not eligible. Participation primarily involves allowing your medical team to share your test results and treatment plans with the research team. Before enrolling, you should talk with your doctor about whether the DCISionRT test is appropriate for your diagnosis and how the results might influence your options for surgery or radiation.